Audit: QRS - Mediterranean Diet for Health & Longevity

Audit conducted on 01/09/2026 09:45 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every gate item, benefit, risk, protocol cell, biomarker row and qualitative item traces to a specific ER passage; spot-checked thresholds (< 80 mg/dL ApoB, 4.9–5.4% HbA1c, 8–12% omega-3 index, 30 mL/min/1.73 m²) all match the ER verbatim.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	marker_11_target carries the ER’s “No established optimal target” hedge; time_1_sub preserves the ER’s “was measured” framing rather than asserting a time-to-effect.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications retain absolute framing; the mercury target retains “track change from own baseline” rather than asserting a threshold.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Contraindications and Key Interactions are drawn only from the ER Key Interactions & Contraindications section; the ALDH2 wine contraindication in Risk-Modifying Factors is correctly not promoted into the stop gate.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, no NCT identifiers, no investigator names and no brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Plain-clinical register matching the ER, including the ER’s own “average blood sugar” and “artery-clogging particle” phrasings.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Benefits card leads with the strongest tier; targets are concrete and actionable without hype.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	All cells are declarative noun phrases and passive constructions, not instructions.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; monitoring targets are presented as reference ranges, and the fixed template disclaimer is unchanged.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrences of recommend/advise/should; e.g. action_3_value uses “Oil and nuts spread across meals” rather than a directive.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in QRS-authored content.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are the ER’s own biomarker names, which are unavoidable in the Monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Gate and tier items are stripped to key facts; no cell carries mechanism or effect sizes.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by full-text scan for you/your/we/our.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (ApoB < 80, hs-CRP < 1.0, fasting insulin 2–6) are optimizer-grade, not population-screening cutoffs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol assumes daily 50 mL high-phenolic olive oil, 30 g nuts and 3+ weekly fish, plus a 12-marker panel.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Includes non-routine tests (omega-3 index, blood mercury, fasting insulin) that a general-population sheet would omit.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	at_a_glance explicitly flags that “gains narrow for anyone already eating well”, the key differentiator for an already-optimizing reader.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Uses “anaphylaxis”, “methylmercury”, “glycated hemoglobin”, “alanine aminotransferase”; plain-language equivalents are carried verbatim from the ER’s own table.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Structural diff against [qrs_template] shows every heading, gate label, tier label and column header byte-identical.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables present; marker_#_* and qualitative_item_# correctly expanded to 12 and 5 numbered instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows differences only inside variable spans and the metadata block; no CSS, markup, comment or footer text altered.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the ER’s High-risk tier carries explanatory prose (“No risk reaches High: …”) rather than an empty-state phrase, and is handled under item 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Core food targets”, action_2_label “Traditional ad-libitum approach” and action_3_label “Single versus divided intake” are verbatim ER bold labels (ER lines 344, 346, 358).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Marker names are verbatim from the ER Monitoring table; time labels derive directly from the ER’s own “Time to effect” bullet wording.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Zero emoji in the file; the ER’s ⚠️ Conflicted markers are correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to key facts only; no cell carries surplus prose, and the print stylesheet and A4 page rule are intact.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13; the preamble text on line 2 is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:04" is quoted, correctly, because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: mediterranean_diet_2026-0901-0424_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0901-0929.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the on-disk filename exactly.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; no stray quoting on git_user, git_issue or any other key.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Mediterranean Diet for Health & Longevity - Quick Reference Sheet”, with the ampersand correctly entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Mediterranean Diet for Health & Longevity”, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0901-0929 → “09/01/2026”.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header block is byte-identical to the template apart from the two variable spans; the ER’s “Also known as” line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses the ER Conclusion’s four paragraphs into pattern definition, strongest outcomes, and the two decision-relevant caveats.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to the ER Conclusion (lines 471–475): pattern composition, “more trial evidence tied to real health outcomes”, the three strongest endpoints, “drawbacks belong to individual components”, and “for someone already eating well, the remaining gain is smaller”.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “type 2 diabetes”, “heart attacks and strokes” and “blood pressure” are all lay terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No hazard ratios, confidence intervals or numeric effect estimates.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items map to the ER’s “Populations who should avoid Mediterranean Diet” list (ER lines 316–324).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All four ER avoid-populations present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Four <li> elements inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	ER trailing clauses such as “for whom the potassium and phosphate load requires supervision” and “for whom the fruit and legume load is not tolerable” are stripped; no dash-trailing content remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“Stage 4–5” staging and the “below 30 mL/min/1.73 m²” threshold retained; the “unless the pattern is rebuilt without those foods” scoping qualifier retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such populations and the section is correctly populated, not empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine items map one-to-one to the ER’s nine interaction bullets (ER lines 298–314), in the same order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine interactions carried; no overlap with the four contraindications.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER “— caution/monitor, " tail and every Mitigation sentence is stripped; the PREDIMED medication-need citation is not carried over.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named drug examples preserved throughout: warfarin/acenocoumarol; lisinopril/amlodipine/losartan; insulin and glipizide; ibuprofen/naproxen; beetroot nitrate, magnesium, garlic extract, hibiscus.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in its interaction list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names nine interactions and the section is correctly populated, not empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets (ER lines 344, 346, 354, 358).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Core food targets (the dose), the ad-libitum protocol variant that carries the hard-endpoint evidence, and divided-versus-single intake — the three decisions a reader must make first.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol contains thirteen bullets, well above three.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine action variables carry substantive ER-derived content; no placeholder text remains.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Cardiovascular events, blood pressure/triglycerides, and average blood sugar/liver enzymes — three of the four intervals given in the ER’s “Time to effect” bullet (ER line 398); the fourth, red-cell omega-3 plateau, is folded into time_3_sub.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order matches the ER’s High-tier benefit ordering: reduced major cardiovascular events, lower blood pressure, then type 2 diabetes and liver endpoints.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER provides four distinct time-to-effect intervals.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Values “4.8–7 years”, “4–8 weeks” and “3–6 months” are verbatim ER intervals with supporting subs.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eleven benefits map to the ER’s eleven Expected Benefits headings, tier for tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated: 5 High, 3 Medium, 2 Low, 1 Speculative, matching the ER exactly.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; no hazard ratios, confidence intervals, trial names or ⚠️ Conflicted qualifiers carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the four benefit spans.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers contain items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven risks map to the ER’s seven risk headings across the Medium, Low and Speculative tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present; High correctly emptied, Medium 3 items, Low 2, Speculative 2.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the bare ER heading; the ER’s relative risks, prevalence percentages and the chickpea-trial detail are all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear anywhere in the four risk spans; the ER’s “(a sudden, severe whole-body allergic reaction)” gloss is stripped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high carries style="display: none" with an HTML comment recording the ER basis, and no empty-state phrasing.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The twelve rows reproduce the ER Monitoring Protocol & Defining Success table (ER lines 428–441) in the same order.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All twelve present: ApoB, LDL-C, triglycerides, glycated hemoglobin, fasting insulin, hs-CRP, ALT, blood pressure, ferritin, vitamin B12, blood mercury, omega-3 index.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Reproduces the ER cadence paragraph (line 426): weekly blood pressure for eight weeks, full panel at 3 and 12 months then annually, warfarin clotting-time recheck at two weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s qualitative-marker list (ER lines 445–453).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five present and verbatim: post-meal energy, gastrointestinal comfort, sleep continuity, training capacity, effortless adherence.

Issues 01/09/2026 09:45

Pass rate 100.00%. No issues found.

Issues 01/09/2026 09:40

1. 4.2 / 4.3 — Key Interaction label paraphrased: The last Key Interaction (QRS line 576) renders the ER bold label “Other intervention interactions” (ER line 314) as “Other interventions”, so the label is neither verbatim nor unabbreviated.

Fixes 01/09/2026 09:40

1. 4.2 / 4.3 — Key Interaction label restored verbatim: The last Key Interaction item was changed from “Other interventions (…)” to “Other intervention interactions (…)”, matching the ER bold label at ER line 314.

Issues 01/09/2026 09:34

1. 1.1 — Daily frequency added to produce targets: [action_1_sub] (QRS line 456) reads “3+ servings vegetables and 3 fruit daily”, but the ER Therapeutic Protocol bullet (ER line 344) states only “3+ servings vegetables, 3 fruit” without a frequency qualifier.
2. 11.2 — Time-to-effect cells misordered: The three time cells run longest-to-shortest duration rather than by benefit magnitude — blood pressure sits in [time_3] (QRS lines 511-518) although the ER ranks Lower Blood Pressure above both type 2 diabetes incidence and the liver-enzyme benefit in its High tier.

Fixes 01/09/2026 09:34

1. 1.1 — Unsupported daily frequency removed: [action_1_sub] changed from “3+ servings vegetables and 3 fruit daily; …” to “3+ servings vegetables, 3 fruit; …”, matching the ER Therapeutic Protocol wording.
2. 11.2 — Time-to-effect cells reordered: Swapped the second and third time cells so blood pressure and triglycerides (4–8 weeks) precede average blood sugar and liver enzymes (3–6 months), matching the ER’s High-tier benefit ranking.